Key Highlights
- 100 percent is the Section 232 tariff rate on patented pharmaceuticals announced in April 2026, with 15 percent for the European Union, Japan, Korea and Switzerland and reduced rates for onshoring plans. Pfizer (NYSE:PFE) closed at USD 29.44 on October 15, within 1.5 percent of its high.
- USD 145.19 was the October 15 close for Merck (NYSE:MRK), down 1.48 percent and about 7.5 percent below the 52-week high of USD 156.92, simple arithmetic. A Dutch court ruling for Halozyme reportedly bars injectable Keytruda sales in eight European markets.
- USD 39.22 was the October 15 close for Novo Nordisk (NYSE:NVO), up 2.89 percent but about 38.9 percent below the 52-week high of USD 64.16, simple arithmetic. BMO cut its target to USD 40 from USD 47, and results are due November 4, 2026.
- USD 3.73 to USD 3.77 is third quarter EPS guidance for AbbVie (NYSE:ABBV), reported below a consensus of USD 3.84, with full-year guidance of USD 13.76 to USD 13.96 under USD 14.01. Results come October 30, 2026 before the open.
Pfizer (NYSE:PFE)
Pfizer rose 0.79 percent to USD 29.44 on October 15, 2026, inside a 52-week range of USD 23.62 to USD 29.88, for a market value near USD 167.8 billion. Under the Section 232 framework, patented drugs face 100 percent unless a company has a pricing agreement or onshoring plan. Pfizer is reported to have secured a three-year tariff respite in an earlier administration deal that included some price cuts. The mechanism is a trade: lower United States prices on selected products in return for relief on import costs. The USD 1.72 annual dividend gives a 5.84 percent yield, with USD 0.43 declared on October 7 and an ex-dividend date of November 6. The FDA approved a Tukysa regimen on October 8, and Florida's Attorney General sued Pfizer and chief executive Albert Bourla on October 2 over COVID-19 vaccine marketing. JPMorgan and BofA hold Neutral ratings with targets of USD 30 and USD 29. The risks are a stock near its high, litigation and a yield that is not guaranteed. Results come November 3, 2026.
Merck (NYSE:MRK)
Merck fell 1.48 percent on October 15, 2026, and the premarket quote was USD 145.99 against a 52-week range of USD 82.01 to USD 156.92. The sharper news is legal. A Dutch court reportedly ruled for Halozyme around October 7 and 8, barring Merck from selling injectable Keytruda in eight European markets. Halozyme holds patents on enzyme technology used to make injectable versions of intravenous drugs, so the case touches Merck's plan to extend the Keytruda franchise before its expected loss of exclusivity later this decade. Offsetting that, Merck presented pivotal Phase 3 oncology data at ESMO on October 13, and its chief executive said the Moderna cancer vaccine should become faster to make over time. RBC cut its target to USD 145 from USD 150, while Citi raised its target to USD 145 from USD 125. Merck pays USD 3.40 a share, a 2.34 percent yield. The risk is an injunction spreading beyond Europe or delaying a subcutaneous launch. Results come October 29, 2026.
Novo Nordisk (NYSE:NVO)
Novo Nordisk is the American depositary receipt of the Danish drugmaker, a certificate that lets United States investors hold the ordinary shares in dollars, so the Danish krone moves the quote. It rose 2.89 percent to USD 39.22 on October 15, 2026, in a 52-week range of USD 35.12 to USD 64.16. Recent news is mixed. The FDA extended its review of the hemophilia A drug denecimig on about October 3 over manufacturing facility issues, and a lawsuit filed on October 15 alleges Ozempic caused vision loss. BMO cut its target to USD 40 from USD 47 with a Market Perform rating, and Citi lowered its target to 296 Danish kroner from 310 with a Neutral rating. Products from the European Union are listed at 15 percent under the tariff framework, but company-specific exposure and any onshoring offsets are not verified. Competition matters too: Eli Lilly grew second quarter revenue 48 percent. The risk is price erosion in obesity drugs. Results come November 4, 2026.
AbbVie (NYSE:ABBV)
AbbVie rose 0.59 percent to USD 283.40 on October 15, 2026, about 2.7 percent below its 52-week high of USD 291.40, simple arithmetic, for a market value near USD 500.8 billion. Around October 6 the company guided third quarter EPS to USD 3.73 to USD 3.77 and full-year EPS to USD 13.76 to USD 13.96, both below published consensus. The cause of the lower guide was not verified here. Clinical news was positive: Skyrizi beat placebo in Crohn's disease in new Phase 3 data presented around October 12, and the FDA granted two Breakthrough Therapy Designations to telisotuzumab adizutecan on October 8. Morgan Stanley set a USD 310 target and BofA USD 305, while UBS is at USD 275. The dividend is USD 6.92 a share, a 2.44 percent yield, and the ex-dividend date was October 15. The risk is that guidance below consensus signals pressure on earnings. Results come October 30, 2026 before the open.
Where Things Stand
It depends, but Pfizer (NYSE:PFE) is best placed on tariff certainty and income, because it is reported to hold a three-year respite and yields 5.84 percent. That strength is partly priced, since the stock sits within 1.5 percent of its high. Merck (NYSE:MRK) carries a European Keytruda injunction. Novo Nordisk (NYSE:NVO) faces the most operating pressure. AbbVie (NYSE:ABBV) reports October 30 after guiding below consensus. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) rose 1.86 percent on October 15, so sector momentum is helping all four. Earnings run from October 29 to November 4, 2026.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...